Shifting tides in the healthcare sector reveal that more and more patients are turning to health systems or IDNs for cancer care. This leads to a couple of questions: what does this mean for oncology and hematology practices, and how can pharma and life science companies effectively engage with healthcare providers (HCPs) from these notoriously […]

To keep up with treatment trends in the ever-shifting oncology landscape, pharma and life science companies rely on real-world data from healthcare professionals (HCPs). HCPs working in cancer care can impart knowledge of the oncology market as it is driven by current practices, as well as provide insights into cutting-edge treatments and developments in patient […]

For some industries, in-person events may not return for quite some time. In the medical and science fields, the shift from live to digital may be permanent. After all, virtual meetings have many advantages. Digital tools let attendees discuss topics, share resources, and network. There’s no need for expensive travel, and busy providers don’t have […]

Although the future of COVID-19 remains unknown, it is clear that the pandemic’s effects will linger in many aspects of cancer care and research, including oncology clinical trials. In a recent JAMA publication, Dr Daniel V. Araujo et al shared their perspectives on the evolving landscape of oncology research. Just as patient visits for treatments and […]

On October 7, 2020, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry 2020 to Emmanuelle Charpentier and Jennifer A. Doudna for their discovery of CRISPR/Cas9 genetic scissors, an innovative technology for genome editing. This technology makes it possible to change the code of life over the course of just a few […]

The COVID-19 pandemic has significantly disrupted the diagnosis and care of patients with cancer in 2020. The long-term consequences of this disruption remain to be seen, but it is anticipated that delays in screening and cancer care may result in a setback in the number of patients diagnosed and successfully treated. During the spring, when […]

Widespread implementation of screening mammography has enabled earlier detection of breast cancer and subsequently improved outcomes. However, there are limitations to current processes, as global access to screening mammography is constrained by availability of specialized radiologists and the potential for variation in performance among human readers. To address these restrictions, artificial intelligence (AI) computer-aided detection […]

The global pandemic has caused seismic changes in the medical and pharma industry. In recent years, the industry has begun a gradual shift toward virtual connections; COVID accelerated these trends, canceling swaths of conferences and conventions. This shift is likely to become permanent in some regions. Attendees and hosts have discovered that virtual tools have […]

Major advances in the treatment of lung cancer, specifically targeted therapies and immunotherapies, have demonstrated a survival benefit in clinical trials. To measure the effects of these advances at the population level, researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, conducted an analysis of the US Surveillance, Epidemiology, and […]

Precision oncology computational methods for diagnosis and treatment selection are generating increased attention in parallel with the increased use of targeted cancer therapies. To outline best practices for ensuring the clinical utility of predictive computational methods in the oncology clinic, the National Cancer Policy Forum and the Board on Mathematical Sciences and Analytics at the […]